These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 8746880)

  • 1. Transvaginal estriol administration in postmenopausal women: a double blind comparative study of two different doses.
    Bottiglione F; Volpe A; Esposito G; Aloysio DD
    Maturitas; 1995 Nov; 22(3):227-32. PubMed ID: 8746880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effectiveness of estriol depot vaginal suppositories in postmenopausal women with urogenital climacteric manifestations].
    Köchli OR; Schär G; Beck B; Benz J
    Gynakol Geburtshilfliche Rundsch; 1992; 32(2):88-91. PubMed ID: 1392633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of sustained-release vaginal oestriol in alleviating urogenital and systemic climacteric complaints.
    Foidart JM; Vervliet J; Buytaert P
    Maturitas; 1991 Jun; 13(2):99-107. PubMed ID: 1921739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Local administration of low-dose estriol and vital Lactobacillus acidophilus in postmenopause].
    Kanne B; Jenny J
    Gynakol Rundsch; 1991; 31(1):7-13. PubMed ID: 1906830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of oral estriol for managing postmenopausal symptoms.
    Takahashi K; Manabe A; Okada M; Kurioka H; Kanasaki H; Miyazaki K
    Maturitas; 2000 Feb; 34(2):169-77. PubMed ID: 10714912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose, vaginally administered estrogens may enhance local benefits of systemic therapy in the treatment of urogenital atrophy in postmenopausal women on hormone therapy.
    Palacios S; Castelo-Branco C; Cancelo MJ; Vázquez F
    Maturitas; 2005 Feb; 50(2):98-104. PubMed ID: 15653006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints versus estradiol-releasing vaginal ring with a vaginal progesterone suppository: clinical and endometrial responses.
    Antoniou G; Kalogirou D; Karakitsos P; Antoniou D; Kalogirou O; Giannikos L
    Maturitas; 1997 Mar; 26(2):103-11. PubMed ID: 9089559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of estriol replacement therapy for climacteric women.
    Yang TS; Tsan SH; Chang SP; Ng HT
    Zhonghua Yi Xue Za Zhi (Taipei); 1995 May; 55(5):386-91. PubMed ID: 7641124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salmon calcitonin plus intravaginal estriol: an effective treatment for the menopause.
    Melis GB; Cagnacci A; Bruni V; Falsetti L; Jasonni VM; Nappi C; Polatti F; Volpe A
    Maturitas; 1996 May; 24(1-2):83-90. PubMed ID: 8794438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of the endometrial safety during intravaginal treatment with estriol.
    Vooijs GP; Geurts TB
    Eur J Obstet Gynecol Reprod Biol; 1995 Sep; 62(1):101-6. PubMed ID: 7493689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Vaginal estriol administration in treatment of postmenopausal urinary incontinence].
    Schmidbauer CP
    Urologe A; 1992 Nov; 31(6):384-9. PubMed ID: 1462489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of low-dose intravaginal estriol on urogenital aging in postmenopausal women.
    Dessole S; Rubattu G; Ambrosini G; Gallo O; Capobianco G; Cherchi PL; Marci R; Cosmi E
    Menopause; 2004; 11(1):49-56. PubMed ID: 14716182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of vaginal estriol and progesterone in postmenopausal women with atrophic vaginitis.
    Chollet JA; Carter G; Meyn LA; Mermelstein F; Balk JL
    Menopause; 2009; 16(5):978-83. PubMed ID: 19390463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: results from a pivotal phase III study.
    Cano A; Estévez J; Usandizaga R; Gallo JL; Guinot M; Delgado JL; Castellanos E; Moral E; Nieto C; del Prado JM; Ferrer J
    Menopause; 2012 Oct; 19(10):1130-9. PubMed ID: 22914208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections.
    Raz R; Stamm WE
    N Engl J Med; 1993 Sep; 329(11):753-6. PubMed ID: 8350884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Estradiol and estriol in the treatment of climacteric symptoms. A controlled trial].
    Bennedsen H; Nielsen JV
    Ugeskr Laeger; 1979 May; 141(22):1471-7. PubMed ID: 377743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and preliminary efficacy of two vaginal gel formulations of ultra-low-dose estriol in postmenopausal women.
    Delgado JL; Estevez J; Radicioni M; Loprete L; Moscoso Del Prado J; Nieto Magro C
    Climacteric; 2016 Apr; 19(2):172-80. PubMed ID: 26786399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Climacteric syndrome: comparison of several secondary therapies].
    Bianco V; Colombo A; Tassan Simonat P
    Ann Ostet Ginecol Med Perinat; 1991; 112(1):54-60. PubMed ID: 1929099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, double-blind, placebo-controlled clinical trial for evaluating the efficacy of fractional CO2 laser compared with topical estriol in the treatment of vaginal atrophy in postmenopausal women.
    Cruz VL; Steiner ML; Pompei LM; Strufaldi R; Fonseca FLA; Santiago LHS; Wajsfeld T; Fernandes CE
    Menopause; 2018 Jan; 25(1):21-28. PubMed ID: 28763401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Topical hormonal treatment and urogenital atrophy].
    Sitruk-Ware R; Thomas JL
    Praxis (Bern 1994); 1997 Aug; 86(33):1245-8. PubMed ID: 9381009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.